Tags:BioTechDevelopmentDrugManagementMarketMedicalMedTechResearchTalentTechnology
Our research expertise on biological mechanisms and pathways has enabled us to develop a pipeline of drug candidates designed to address important unmet clinical needs, including better management of complications related to kidney and cardiovascular diseases, with the goal of improving outcomes for this large population of underserved patients. Our lead candidate tenapanor, is a first-in-class, targeted, small molecule for the control of serum phosphorus in adult patients with chronic kidney disease on dialysis. We are also developing earlier-stage candidates that further leverage our discovery capabilities and deep understanding of transport mechanisms, targeting specific pharmacologic pathways. Ardelyx is publicly traded on the Nasdaq Global Market under the symbol ARDX. Tapping into the best talent on both coasts and everywhere in between, we maintain dual headquarters in the greater San Francisco and Boston biotech communities.
Likes
92
Location: United States, Fremont
Phone: +1 510-745-1700
Total raised: $55M

Investors 2

Funding Rounds 2

DateSeriesAmountInvestorsDeal News
15.05.2014-$25M--
31.08.2011Series B$30M--

Mentions in press and media 15

DateTitleDescriptionCategoryAuthorSource
03.09.2021Ardelyx An... FREMONT, Calif. and WALTHAM,...--prnewswire...
29.07.2021Ardelyx Re... FREMONT, Calif. and WALTHAM,...--prnewswire...
29.07.2021Ardelyx : ...FREMONT, Calif. and WALTHAM, M...--marketscre...
07.06.2021Ardelyx An... FREMONT, Calif. and WALTHAM,...--prnewswire...
29.04.2021Ardelyx An... FREMONT, Calif. and WALTHAM,...--prnewswire...
14.04.2021Ardelyx Co... FREMONT, Calif. and WALTHAM,...--prnewswire...
12.04.2021Ardelyx An... FREMONT, Calif. and WALTHAM,...--prnewswire...
30.03.2021Ardelyx An... FREMONT, Calif. and WALTHAM,...--prnewswire...
13.02.2021An­oth­er ...As the FDA’s decision date on ...-Kyle Blank...endpts.com...
22.10.2020Ardelyx La... FREMONT, Calif., Oct. 22, 20...--prnewswire...
Show more